Switch to:
Also traded in: Germany, Israel, Mexico, Switzerland, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.03
TEVJF's Cash-to-Debt is ranked lower than
97% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. TEVJF: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
TEVJF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.22 Max: 1.03
Current: 0.03
0.03
1.03
Equity-to-Asset 0.36
TEVJF's Equity-to-Asset is ranked lower than
83% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. TEVJF: 0.36 )
Ranked among companies with meaningful Equity-to-Asset only.
TEVJF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.48 Max: 0.59
Current: 0.36
0.36
0.59
Interest Coverage 3.90
TEVJF's Interest Coverage is ranked lower than
84% of the 635 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 105.95 vs. TEVJF: 3.90 )
Ranked among companies with meaningful Interest Coverage only.
TEVJF' s Interest Coverage Range Over the Past 10 Years
Min: 3.6  Med: 11.22 Max: 20.32
Current: 3.9
3.6
20.32
Piotroski F-Score: 3
Altman Z-Score: 0.80
Beneish M-Score: -2.26
WACC vs ROIC
3.96%
3.13%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 9.83
TEVJF's Operating Margin % is ranked higher than
54% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. TEVJF: 9.83 )
Ranked among companies with meaningful Operating Margin % only.
TEVJF' s Operating Margin % Range Over the Past 10 Years
Min: 8.12  Med: 17.02 Max: 25.46
Current: 9.83
8.12
25.46
Net Margin % 1.50
TEVJF's Net Margin % is ranked lower than
68% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. TEVJF: 1.50 )
Ranked among companies with meaningful Net Margin % only.
TEVJF' s Net Margin % Range Over the Past 10 Years
Min: 1.5  Med: 12.03 Max: 20.75
Current: 1.5
1.5
20.75
ROE % 0.21
TEVJF's ROE % is ranked lower than
70% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. TEVJF: 0.21 )
Ranked among companies with meaningful ROE % only.
TEVJF' s ROE % Range Over the Past 10 Years
Min: 0.22  Med: 10 Max: 16.18
Current: 0.21
0.22
16.18
ROA % 0.46
TEVJF's ROA % is ranked lower than
66% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. TEVJF: 0.46 )
Ranked among companies with meaningful ROA % only.
TEVJF' s ROA % Range Over the Past 10 Years
Min: 0.45  Med: 4.95 Max: 9.26
Current: 0.46
0.45
9.26
ROC (Joel Greenblatt) % 18.36
TEVJF's ROC (Joel Greenblatt) % is ranked higher than
57% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. TEVJF: 18.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TEVJF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 16.41  Med: 33.56 Max: 49.79
Current: 18.36
16.41
49.79
3-Year Revenue Growth Rate -1.60
TEVJF's 3-Year Revenue Growth Rate is ranked lower than
74% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. TEVJF: -1.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TEVJF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.6  Med: 14.9 Max: 37.4
Current: -1.6
-1.6
37.4
3-Year EBITDA Growth Rate -7.20
TEVJF's 3-Year EBITDA Growth Rate is ranked lower than
77% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. TEVJF: -7.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TEVJF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -10.5  Med: 16.3 Max: 47.4
Current: -7.2
-10.5
47.4
3-Year EPS without NRI Growth Rate -63.90
TEVJF's 3-Year EPS without NRI Growth Rate is ranked lower than
98% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. TEVJF: -63.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TEVJF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -63.9  Med: 16 Max: 119.7
Current: -63.9
-63.9
119.7
GuruFocus has detected 5 Warning Signs with Teva Pharmaceutical Industries Ltd $TEVJF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TEVJF's 10-Y Financials

Financials (Next Earnings Date: 2017-05-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with OTCPK:TEVJF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Teva Pharmaceutical Industries Ltd

SymbolPriceYieldDescription
TEVVF555.0112.617 % Conv.Cum.Pfd Shs Mandatory Conv. 15.12.2018

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:NYSE:ZTS, OTCPK:TKPYY, NAS:MYL, OTCPK:ESALF, OTCPK:SGIOY, OTCPK:MKGAY, OTCPK:MTZPY, OTCPK:APNHF, NYSE:PRGO, OTCPK:HLUYY, OTCPK:SFOSF, OTCPK:IPSEY, OTCPK:ORINY, OTCPK:TAISF, NYSE:RDY, OTCPK:HKMPF, OTCPK:HYPMY, NYSE:TARO, NYSE:MNK, NAS:OPK » details
Traded in other countries:TEV.Germany, TEVA.Israel, TEVAN.Mexico, TEVA.Switzerland, TEVA.USA,
Headquarter Location:Israel
Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Its products include Copaxone, Azilect and Provigil.

Headquartered in Israel, Teva Pharmaceutical is the world's largest generic pharmaceutical manufacturer. The company also develops and sells branded pharmaceuticals in central nervous system, oncology, respiratory, and women's health categories. After acquiring Allergan's generics business, Teva's generic sales should be over 60% of total revenue, with branded drug and international over-the-counter revenue making up the balance of sales. Copaxone makes up about half of Teva's branded drug segment, with about $4 billion in sales for 2015.

Ratios

vs
industry
vs
history
PE Ratio 518.83
TEVJF's PE Ratio is ranked lower than
99% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.48 vs. TEVJF: 518.83 )
Ranked among companies with meaningful PE Ratio only.
TEVJF' s PE Ratio Range Over the Past 10 Years
Min: 10.49  Med: 20.77 Max: 938.25
Current: 518.83
10.49
938.25
Forward PE Ratio 6.63
TEVJF's Forward PE Ratio is ranked higher than
93% of the 202 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. TEVJF: 6.63 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 518.83
TEVJF's PE Ratio without NRI is ranked lower than
99% of the 544 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.85 vs. TEVJF: 518.83 )
Ranked among companies with meaningful PE Ratio without NRI only.
TEVJF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.49  Med: 20.77 Max: 938.25
Current: 518.83
10.49
938.25
Price-to-Owner-Earnings 13.21
TEVJF's Price-to-Owner-Earnings is ranked higher than
84% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.45 vs. TEVJF: 13.21 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TEVJF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.09  Med: 15.84 Max: 67.1
Current: 13.21
9.09
67.1
PB Ratio 1.06
TEVJF's PB Ratio is ranked higher than
86% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. TEVJF: 1.06 )
Ranked among companies with meaningful PB Ratio only.
TEVJF' s PB Ratio Range Over the Past 10 Years
Min: 1.06  Med: 2.13 Max: 2.98
Current: 1.06
1.06
2.98
PS Ratio 1.35
TEVJF's PS Ratio is ranked higher than
75% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. TEVJF: 1.35 )
Ranked among companies with meaningful PS Ratio only.
TEVJF' s PS Ratio Range Over the Past 10 Years
Min: 1.35  Med: 2.65 Max: 4.33
Current: 1.35
1.35
4.33
Price-to-Free-Cash-Flow 6.82
TEVJF's Price-to-Free-Cash-Flow is ranked higher than
90% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.83 vs. TEVJF: 6.82 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TEVJF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.82  Med: 13.95 Max: 33.07
Current: 6.82
6.82
33.07
Price-to-Operating-Cash-Flow 5.65
TEVJF's Price-to-Operating-Cash-Flow is ranked higher than
89% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.62 vs. TEVJF: 5.65 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TEVJF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.65  Med: 11.02 Max: 23.43
Current: 5.65
5.65
23.43
EV-to-EBIT 53.04
TEVJF's EV-to-EBIT is ranked lower than
87% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. TEVJF: 53.04 )
Ranked among companies with meaningful EV-to-EBIT only.
TEVJF' s EV-to-EBIT Range Over the Past 10 Years
Min: 12  Med: 20.9 Max: 114.5
Current: 53.04
12
114.5
EV-to-EBITDA 25.11
TEVJF's EV-to-EBITDA is ranked lower than
74% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. TEVJF: 25.11 )
Ranked among companies with meaningful EV-to-EBITDA only.
TEVJF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.1  Med: 14.8 Max: 60.3
Current: 25.11
9.1
60.3
Shiller PE Ratio 13.46
TEVJF's Shiller PE Ratio is ranked higher than
93% of the 161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.67 vs. TEVJF: 13.46 )
Ranked among companies with meaningful Shiller PE Ratio only.
TEVJF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 13.48  Med: 27.72 Max: 73.59
Current: 13.46
13.48
73.59
Current Ratio 0.92
TEVJF's Current Ratio is ranked lower than
90% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. TEVJF: 0.92 )
Ranked among companies with meaningful Current Ratio only.
TEVJF' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.6 Max: 2.95
Current: 0.92
0.92
2.95
Quick Ratio 0.65
TEVJF's Quick Ratio is ranked lower than
90% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. TEVJF: 0.65 )
Ranked among companies with meaningful Quick Ratio only.
TEVJF' s Quick Ratio Range Over the Past 10 Years
Min: 0.65  Med: 1.03 Max: 2.18
Current: 0.65
0.65
2.18
Days Inventory 161.01
TEVJF's Days Inventory is ranked lower than
71% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. TEVJF: 161.01 )
Ranked among companies with meaningful Days Inventory only.
TEVJF' s Days Inventory Range Over the Past 10 Years
Min: 162.08  Med: 186.4 Max: 208.14
Current: 161.01
162.08
208.14
Days Sales Outstanding 125.37
TEVJF's Days Sales Outstanding is ranked lower than
78% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. TEVJF: 125.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEVJF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 95.91  Med: 123.91 Max: 153.21
Current: 125.37
95.91
153.21
Days Payable 78.39
TEVJF's Days Payable is ranked higher than
56% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. TEVJF: 78.39 )
Ranked among companies with meaningful Days Payable only.
TEVJF' s Days Payable Range Over the Past 10 Years
Min: 78.39  Med: 84.39 Max: 111.41
Current: 78.39
78.39
111.41

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.02
TEVJF's Dividend Yield % is ranked higher than
92% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. TEVJF: 4.02 )
Ranked among companies with meaningful Dividend Yield % only.
TEVJF' s Dividend Yield % Range Over the Past 10 Years
Min: 0.62  Med: 2.02 Max: 4.37
Current: 4.02
0.62
4.37
Dividend Payout Ratio 19.43
TEVJF's Dividend Payout Ratio is ranked lower than
100% of the 410 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.35 vs. TEVJF: 19.43 )
Ranked among companies with meaningful Dividend Payout Ratio only.
TEVJF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.14  Med: 0.42 Max: 19.43
Current: 19.43
0.14
19.43
3-Year Dividend Growth Rate 2.00
TEVJF's 3-Year Dividend Growth Rate is ranked lower than
65% of the 285 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. TEVJF: 2.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
TEVJF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -6.7  Med: 23.6 Max: 80.9
Current: 2
-6.7
80.9
Forward Dividend Yield % 4.02
TEVJF's Forward Dividend Yield % is ranked higher than
90% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.59 vs. TEVJF: 4.02 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 6.19
TEVJF's 5-Year Yield-on-Cost % is ranked higher than
92% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.09 vs. TEVJF: 6.19 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TEVJF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.95  Med: 3.11 Max: 6.8
Current: 6.19
0.95
6.8
3-Year Average Share Buyback Ratio -2.30
TEVJF's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. TEVJF: -2.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TEVJF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.6  Med: -2.7 Max: 3.2
Current: -2.3
-12.6
3.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.49
TEVJF's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
97% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. TEVJF: 0.49 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TEVJF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.57  Med: 2.43 Max: 7.57
Current: 0.49
0.57
7.57
Price-to-Median-PS-Value 0.51
TEVJF's Price-to-Median-PS-Value is ranked higher than
92% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. TEVJF: 0.51 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TEVJF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.34  Med: 1.12 Max: 2.1
Current: 0.51
0.34
2.1
Earnings Yield (Greenblatt) % 1.89
TEVJF's Earnings Yield (Greenblatt) % is ranked lower than
60% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. TEVJF: 1.89 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TEVJF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.9  Med: 4.8 Max: 8.4
Current: 1.89
0.9
8.4
Forward Rate of Return (Yacktman) % 13.09
TEVJF's Forward Rate of Return (Yacktman) % is ranked lower than
54% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.72 vs. TEVJF: 13.09 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TEVJF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 10  Med: 18.5 Max: 44.5
Current: 13.09
10
44.5

More Statistics

Revenue (TTM) (Mil) $21,903
EPS (TTM) $ 0.06
Beta-0.28
Short Percentage of Float0.00%
52-Week Range $33.50 - 60.76
Shares Outstanding (Mil)1,014.99

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 23,574 23,485 24,026
EPS ($) 4.78 4.73 5.11
EPS without NRI ($) 4.78 4.73 5.11
EPS Growth Rate
(Future 3Y To 5Y Estimate)
0.83%
Dividends per Share ($) 1.36 1.43 1.65
» More Articles for OTCPK:TEVJF

Headlines

Articles On GuruFocus.com
Stocks That Fell to 3-Year Lows in the Week of April 14 Apr 22 2017 
What Will Make Man Smarter? Apr 10 2017 
Risk-Reward With Teva Pharmaceutical Mar 27 2017 
23 Questions With the Founder of WayUndervalued.com Mar 26 2017 
Valeant: It's Not a Game of Chess Part I Mar 16 2017 
Who Is Winning the Fight Against Opioid Abuse? Feb 27 2017 
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017 
Beaten-Down Valuation and a 3% Dividend Yield Feb 07 2017 
Naltrexone Showing More Potential in Drug Addiction Treatment Market Feb 05 2017 
John Paulson's Bargain Stock Jan 30 2017 

More From Other Websites
3 Dividend Stocks That Retirees Should Avoid Apr 22 2017
Teva's new asthma inhaler poses first competition for GSK's Advair Apr 20 2017
Teva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone... Apr 20 2017
Teva Showcases CNS Portfolio at 69th Annual Meeting of the American Academy of Neurology Apr 19 2017
Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Valeant Pharmaceuticals Apr 19 2017
The Billionaire And The Drug Price-Fixing Scandal Apr 18 2017
U.S. FDA raises concerns over Teva's plant in China Apr 13 2017
Neurocrine Avoids Suicide Warning In Teva-Rivaling Drug; Stock Pops Apr 12 2017
Cenovus  Energy, DryShips Dip into Wednesday’s 52-Week Low Club Apr 12 2017
Approval For Neurocrine's Ingrezza Was No Surprise, But Lack Of Warning Label A Big Advantage Over... Apr 12 2017
Neurocrine Outperforms Even Bullish Estimates Of Ingrezza Approval Upside Apr 12 2017
Why Neurocrine Biosciences Stock Is Soaring Higher Today Apr 12 2017
What Will Make Man Smarter? Apr 10 2017
Teva Pharmaceutical Said to Be Exploring Sale of Women's Health Unit Apr 07 2017
Teva to Report First Quarter 2017 Financial Results on May 11, 2017 Apr 06 2017
Celgene (CELG) Gets Paragraph IV Notice Letter for Pomalyst Apr 05 2017
History Comes Back to Haunt Teva Pharmaceutical Industries, Sending Shares Down 8% in March Apr 05 2017
Why Teva stock isn’t moving on its major Huntington’s disease drug approval Apr 05 2017
Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Neurocrine Biosciences Apr 05 2017
An Israeli pharma firm has found a way to make drugs longer lasting and more effective Apr 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)